anti-malaria drugs

Former pharmaceutical executive Martin Shkreli has congratulated a group of Australian students who reproduced the active ingredient for a life-saving, anti-parasitic drug at the centre of a drug-price controversy involving his former company. The students from Sydney Grammar School drew global media attention this week after they said they had produced the drug Daraprim for about $2 a dose, a fraction of the current list price of $750 per dose. Shkreli is a former chief executive of Turing Pharmaceuticals, where he sparked outrage among patients and U.S. lawmakers for raising the price of Daraprim by more than 5,000%...

Read More »